PUBLIC CONSERVATION LAND AND EMPLOYMENT GROWTH IN THE NORTHERN FOREST REGION

As with many environmental issues, debates about increasing public conservation lands in the Northern Forest region frequently center on a perceived tradeoff between jobs and the environment. In particular, opponents of conservation lands often argue that employment will decline significantly when land is diverted from commodity-oriented uses such as wood products production. To evaluate this claim, we estimate a model of simultaneous employment and net migration growth using data on the 92 non-metropolitan counties comprising the region. Growth in employment and net migration are measured over the period 1990 to 1997 and the set of exogenous variables includes the 1990 share of the county land base in public conservation uses. We find that net migration rates were systematically higher in counties with more conservation lands, but the effects are relatively small. Public conservation lands were found to have no systematic effect on employment growth over the 1990 to 1997 period. Two extensions are considered. We examine the separate effects of preservationist and multiple-use lands. We also identify a "natural experiment" involving changes in national forest management that allows us to estimate the effects of diverting private forestland to public conservation uses. Our central conclusions are that existing public conservation lands have a positive, but small, effect on employment and migration in the Northern Forest region and that, over the range of our data, employment and migration are unlikely to be affected by timber harvest reductions resulting from the establishment of new conservation lands.Labor and Human Capital, Land Economics/Use,

Cellular delivery of antibodies: effective targeted subcellular imaging and new therapeutic tool

It is already more than a century since the pioneering work of the Nobel Laureate Ehrlich gave birth to the side chain theory1, which helped to define antibodies and their ability to target specific biological sites. However, the use of antibodies is still restricted to the extracellular space due to the lack of a suitable delivery vehicle for the efficient transport of antibodies into live cells without inducing toxicity. In this work, we report the efficient encapsulation and delivery of antibodies into live cells with no significant loss of cell viability or any deleterious affect on the cell metabolic activity. This delivery system is based on poly(2-(methacryloyloxy)ethyl phosphorylcholine)-block-(2-(diisopropylamino)ethyl methacrylate), (PMPC-PDPA), a pH sensitive diblock copolymer that self-assembles to form nanometer-sized vesicles, also known as polymersomes, at physiological pH. These polymersomes can successfully deliver relatively high antibody payloads within live cells. Once inside the cells, we demonstrate that these antibodies can target their epitope by immune-labelling of cytoskeleton, Golgi, and transcription factor proteins in live cells. We also demonstrate that this effective antibody delivery mechanism can be used to control specific subcellular events, as well as modulate cell activity and pro-inflammatory process

Hypoxia as a target for drug combination therapy of liver cancer

Hepatocellular carcinoma (HCC) is the third most frequentcause of cancer deaths worldwide. The standard of care for intermediate HCC is transarterial chemoembolization, which combines tumour embolization with locoregional delivery of the chemotherapeutic doxorubicin. Embolization therapies induce hypoxia, leading to the escape and proliferation of hypoxia-adapted cancer cells. The transcription factor that orchestrates responses to hypoxia is hypoxia-inducible factor 1 (HIF-1). The aim of this work is to show that targeting HIF-1 with combined drug therapy presents an opportunity for improving outcomes for HCC treatment. HepG2 cells were cultured under normoxic and hypoxic conditions exposed to doxorubicin, rapamycin and combinations thereof, and analyzed for viability and the expression of hypoxia-induced HIF-1α in response to these treatments. A pilot study was carried out to evaluate the antitumour effects of these drug combinations delivered from drug-eluting beads in vivo using an ectopic xenograft murine model of HCC. A therapeutic doxorubicin concentration that inhibits the viability of normoxic and hypoxic HepG2 cells and above which hypoxic cells are chemoresistant was identified, together with the lowest effective dose of rapamycin against normoxic and hypoxicHepG2 cells. It was shown that combinations of rapamycinand doxorubicin are more effective than doxorubicin alone. Western Blotting indicated that both doxorubicin and rapamycin inhibit hypoxia-induced accumulation of HIF-1α. Combination treatments were more effective in vivo than either treatment alone. mTOR inhibition can improve outcomes of doxorubicin treatment in HCC Anti-Cancer

Eye tracking and visualization. Introduction to the Special Thematic Issue

There is a growing interest in eye tracking technologies applied to support traditional visualization techniques like diagrams, charts, maps, or plots, either static, animated, or interactive ones. More complex data analyses are required to derive knowledge and meaning from the data. Eye tracking systems serve that purpose in combination with biological and computer vision, cognition, perception, visualization,  human-computer-interaction, as well as usability and user experience research. The 10 articles collected in this thematic special issue provide interesting examples how sophisticated methods of data analysis and representation enable researchers to discover and describe fundamental spatio-temporal regularities in the data. The human visual system, supported by appropriate visualization tools, enables the human operator to solve complex tasks, like understanding and interpreting three-dimensional medical images, controlling air traffic by radar displays, supporting instrument flight tasks, or interacting with virtual realities. The development and application of new visualization techniques is of major importance for future technological progress

Symmetry Theorems and Uniform Rectifiability

We study overdetermined boundary conditions for positive solutions to some elliptic partial differential equations of p-Laplacian type in a bounded domain D. We show that these conditions imply uniform rectifiability of ∂D and also that they yield the solution to certain symmetry problems

Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer

DC Bead is a drug delivery embolisation system that can be loaded with doxorubicin or irinotecan for the treatment of a variety of liver cancers. In this study we demonstrate that the topoisomerase I inhibitor topotecan hydrochloride can be successfully loaded into the DC Bead sulfonate-modified polyvinyl alcohol hydrogel matrix, resulting in a sustained-release drug eluting bead (DEBTOP) useful for therapeutic purposes. The in vitro drug loading capacity, elution characteristics and the effects on mechanical properties of the beads are described with reference to our previous work with irinotecan hydrochloride (DEBIRI). Results showed that drug loading was faster when the solution was agitated compared to static loading and a maximum loading of ca. 40–45 mg topotecan in 1 ml hydrated beads was achievable. Loading the drug into the beads altered the size, compressibility moduli and colour of the bead. Elution was shown to be reliant on the presence of ions to perform the necessary exchange with the electrostatically bound topotecan molecules. Topotecan was shown by MTS assay to have an IC50 for human pancreatic adenocarcinoma cells (PSN-1) of 0.22 and 0.27 lM compared to 28.1 and 19.2 lM for irinotecan at 48 and 72 h, respectively. The cytotoxic efficacy of DEBTOP on PSN-1 was compared to DEBIRI. DEPTOP loaded at 6 & 30 mg ml-1, like its free drug form, was shown to be more potent than DEBIRI of comparable doses at 24, 48 & 72 h using a slightly modified MTS assay. Using a PSN-1 mouse xenograft model, DEBIRI doses of 3.3–6.6 mg were shown to be well tolerated (even with repeat administration) and effective in reducing the tumour size. DEBTOP however, was lethal after 6 days at doses of 0.83–1.2 mg but demonstrated reasonable efficacy and tolerability (again with repeat injection possible) at 0.2–0.4 mg doses. Care must therefore be taken when selecting the dose of topotecan to be loaded into DC Bead given its greater potency and potential toxicity